Testicular cancer medical therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
|
Testicular cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Testicular cancer medical therapy On the Web |
|
American Roentgen Ray Society Images of Testicular cancer medical therapy |
|
Risk calculators and risk factors for Testicular cancer medical therapy |
Overview
Before 1970, the young man with recurrent testicular cancer was destined to have rapid progression and death from disseminated disease. Currently, although 7000 to 8000 new cases of testicular cancer occur in the United States yearly, only 400 men are expected to die of the disease. Much of this improvement is due to advances in adjuvant therapy.
Due to the risk of subsequent metastasis, post-surgical adjuvant therapy may be offered to the patient following orchiectomy. The type of adjuvant therapy depends largely on the histology of the tumor and the stage of progression at the time of surgery. These two factors contribute to the risk of recurrence, including metastasis. Adjuvant treatments may involve chemotherapy, radiotherapy or careful surveillance by frequent CT scans and blood tests by oncologists.